195 related articles for article (PubMed ID: 35586617)
1. Utilization, Spending, and Price of Opioid Medications in the US Medicaid Programs Between 1991 and 2019.
Alsultan MM; Guo JJ
Am Health Drug Benefits; 2022 Mar; 15(1):31-37. PubMed ID: 35586617
[TBL] [Abstract][Full Text] [Related]
2. Utilization, spending, and price trends for short- and long-acting Beta-agonists and inhaled corticosteroids in the medicaid program, 1991-2010.
Chiu SF; Kelton CM; Guo JJ; Wigle PR; Lin AC; Szeinbach SL
Am Health Drug Benefits; 2011 May; 4(3):140-9. PubMed ID: 25126346
[TBL] [Abstract][Full Text] [Related]
3. Trends in Utilization, Spending, and Prices of Smoking-Cessation Medications in Medicaid Programs: 25 Years Empirical Data Analysis, 1991-2015.
Yue X; Guo JJ; Wigle PR
Am Health Drug Benefits; 2018 Sep; 11(6):275-285. PubMed ID: 30464795
[TBL] [Abstract][Full Text] [Related]
4. A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database.
Le H; Hong H; Ge W; Francis H; Lyn-Cook B; Hwang YT; Rogers P; Tong W; Zou W
Exp Biol Med (Maywood); 2023 Nov; 248(21):1944-1951. PubMed ID: 38158803
[TBL] [Abstract][Full Text] [Related]
5. Spending, Utilization, and Price Trends for Immune Checkpoint Inhibitors in US Medicaid Programs: An Empirical Analysis from 2011 to 2021.
Shin YE; Kumar A; Guo JJ
Clin Drug Investig; 2023 Apr; 43(4):289-298. PubMed ID: 37005969
[TBL] [Abstract][Full Text] [Related]
6. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.
Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
Ann Pharmacother; 2012 Apr; 46(4):503-12. PubMed ID: 22454448
[TBL] [Abstract][Full Text] [Related]
7. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
[TBL] [Abstract][Full Text] [Related]
8. Patterns in opioid prescription in the United States by region and prescribers over a 4-year period.
Bigal LM; Bibeau K; Dumbar S
J Opioid Manag; 2019; 15(6):499-506. PubMed ID: 31850512
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Institutional Opioid Equianalgesia Tools: A National Study.
Wen RY; Atayee RS; Edmonds KP
J Palliat Med; 2022 Nov; 25(11):1686-1691. PubMed ID: 35559657
[No Abstract] [Full Text] [Related]
10. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
Alrasheed M; Hincapie AL; Guo JJ
J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
[TBL] [Abstract][Full Text] [Related]
11. Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014.
Liang D; Bao Y; Wallace M; Grant I; Shi Y
Addiction; 2018 Nov; 113(11):2060-2070. PubMed ID: 29989239
[TBL] [Abstract][Full Text] [Related]
12. Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years' Experience 1991-2015.
Almalki ZS; Yue X; Xia Y; Wigle PR; Guo JJ
Pharmacoecon Open; 2017 Jun; 1(2):123-131. PubMed ID: 29442334
[TBL] [Abstract][Full Text] [Related]
13. Online Conversation Monitoring to Understand the Opioid Epidemic: Epidemiological Surveillance Study.
Black JC; Margolin ZR; Olson RA; Dart RC
JMIR Public Health Surveill; 2020 Jun; 6(2):e17073. PubMed ID: 32597786
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical payments to physicians may increase prescribing for opioids.
Nguyen TD; Bradford WD; Simon KI
Addiction; 2019 Jun; 114(6):1051-1059. PubMed ID: 30667135
[TBL] [Abstract][Full Text] [Related]
15. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
[TBL] [Abstract][Full Text] [Related]
16. Utilization, reimbursement, and price trends for Hepatitis C virus medications in the US Medicaid programs: 2001-2021.
Gari MH; Alsuhibani A; Alashgar A; Guo JJ
Explor Res Clin Soc Pharm; 2023 Dec; 12():100383. PubMed ID: 38145237
[TBL] [Abstract][Full Text] [Related]
17. Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
Costa LSD; Alsultan MM; Hincapie AL; Guo JJ
J Thromb Thrombolysis; 2023 Feb; 55(2):339-345. PubMed ID: 36401731
[TBL] [Abstract][Full Text] [Related]
18. Crowdsourcing black market prices for prescription opioids.
Dasgupta N; Freifeld C; Brownstein JS; Menone CM; Surratt HL; Poppish L; Green JL; Lavonas EJ; Dart RC
J Med Internet Res; 2013 Aug; 15(8):e178. PubMed ID: 23956042
[TBL] [Abstract][Full Text] [Related]
19. Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018.
Elsisi Z; Hincapie AL; Guo JJ
Am Health Drug Benefits; 2020 May; 13(2):74-84. PubMed ID: 32724502
[TBL] [Abstract][Full Text] [Related]
20. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period.
Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ
Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
